Stifel Reiterates Buy Rating on Fulcrum Therapeutics (FULC)

March 29, 2022 5:22 PM EDT Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $43.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login